Ranbaxy under fire: Will India's pharma industry be hit?

00 million fine on Ranbaxy by US authorities after it pleaded guilty to "felony charges" for violating drug manufacturing norms is "a wake up call" for Indian pharmaceutical industry, according to Biocon Chairman and Manging Director Kiran ...

It will now be difficult to talk about the innovative capabilities of the Indian generic drug industry with undiluted pride. What do you do when a company that you admired and cited as an example bites the dust? This is a real peril for management teachers.

Torrent Pharma | Pennar Industries | McNally Bharat | YES Bank | Jet Airways | CRISIL | Ranbaxy Labs | Midland Polymer | Fortis Healthcare and Just Dial are stocks, which are in the news today.

India's pharmaceutical industry has been dealt a major blow by the Ranbaxy Laboratories settlement in which the company accepted charges of fraud and poor quality. Wockhardt's Aurangabad plant being disqualified to supply drugs to the US, quick on ...

NEW DELHI: India, known as the "pharmacy to the world", defended on Monday its lucrative generic drug industry as safe and tightly regulated, after the nation's biggest drug firm pleaded guilty last month to US charges of making adulterated ...

Pharma major Zydus Cadila believes that despite the recent Ranbaxy episode involving adulterated generic drugs, the pharma industry does not need more domestic and international regulation. According to Chief Operating Officer Ganesh Nayak, it is also wholly ...

Few isolated cases cannot undermine well regulated system, says commerce ministry The Indian government appears to be keen to protect the reputation of the Indian pharma industry, which has been dented by the recent incident of Ranbaxy pleading guilty to ...

Ex-Ranbaxy executive Dinesh Thakur speaks about implications of FDA order on Indian generic drugs industry Vidya Krishnan Dinesh Thakur says he wishes Ranbaxy and its management had responded by doing things the right way. Also Read Updated: Thu, ...

Drug makers worry that the Ranbaxy example puts the entire Indian industry under the bracket of “dirty” manufacturers. MUMBAI: Indian drug makers, who had built their billion dollar fortunes by exporting generic drugs to the US market, may find it ...